Little information is available on how the types, concentrations, and distribution of chemicals have evolved over the years. The objective of the present study is therefore to review the spatial and .Show moreLittle information is available on how the types, concentrations, and distribution of chemicals have evolved over the years. The objective of the present study is therefore to review the spatial and temporal distribution profile of emerging contaminants with limited toxicology data in the pearl river basin over the years to build up the emerging contaminants database in this region for risk assessment and regulatory purposes. The result revealed that seven groups of emerging contaminants were abundant in this region, and many emerging contaminants had been detected at much higher concentrations before 2011. Specifically, antibiotics, phenolic compounds, and acidic pharmaceuticals were the most abundant emerging contaminants detected in the aquatic compartment, while phenolic compounds were of the most profound concern in soil. Flame retardants and plastics were the most frequently studied chemicals in organisms. The abundance of the field concentrations and frequencies varied considerably over the years, and currently available data can hardly be used for regulation purposes. It is suggested that watershed management should establish a regular monitoring scheme and comprehensive database to monitor the distribution of emerging contaminants considering the highly condensed population in this region. The priority monitoring list should be formed in consideration of historical abundance, potential toxic effects of emerging contaminants as well as the distribution of heavily polluting industries in the region. Show less
In March 2022, the first ISMRM Workshop on Low-Field MRI was held virtually. The goals of this workshop were to discuss recent low field MRI technology including hardware and software developments,... Show moreIn March 2022, the first ISMRM Workshop on Low-Field MRI was held virtually. The goals of this workshop were to discuss recent low field MRI technology including hardware and software developments, novel methodology, new contrast mechanisms, as well as the clinical translation and dissemination of these systems. The virtual Workshop was attended by 368 registrants from 24 countries, and included 34 invited talks, 100 abstract presentations, 2 panel discussions, and 2 live scanner demonstrations. Here, we report on the scientific content of the Workshop and identify the key themes that emerged. The subject matter of the Workshop reflected the ongoing developments of low-field MRI as an accessible imaging modality that may expand the usage of MRI through cost reduction, portability, and ease of installation. Many talks in this Workshop addressed the use of computational power, efficient acquisitions, and contemporary hardware to overcome the SNR limitations associated with low field strength. Participants discussed the selection of appropriate clinical applications that leverage the unique capabilities of low-field MRI within traditional radiology practices, other point-of-care settings, and the broader community. The notion of "image quality" versus "information content" was also discussed, as images from low-field portable systems that are purpose-built for clinical decision-making may not replicate the current standard of clinical imaging. Speakers also described technical challenges and infrastructure challenges related to portability and widespread dissemination, and speculated about future directions for the field to improve the technology and establish clinical value. Show less
The synthetic vasopressin (AVP) analogue desmopressin (dDAVP) has been used as pharmacological function test to quantify vasopressinergic co-activation of the hypothalamus pituitary adrenal (HPA)... Show moreThe synthetic vasopressin (AVP) analogue desmopressin (dDAVP) has been used as pharmacological function test to quantify vasopressinergic co-activation of the hypothalamus pituitary adrenal (HPA) axis in the past. Such exogenous vasopressinergic stimulation may induce confounding cardiovascular, pro-coagulatory and anti-diuretic effects and low endogenous corticotrophin-releasing-hormone (CRH) levels may limit its potential to reliably assess co-activation. Alternatively, the dopamine-2-(D2)-antagonist metoclopramide is believed to induce co-activation indirectly by releasing endogenous AVP. We investigated this indirect co-activation with metoclopramide under conditions of low and enhanced endogenous CRH release in healthy volunteers. A randomized, double-blind, placebo-controlled, four-way crossover study was performed in 12 healthy males. CRH release was induced by administering an oral 5-hydroxytryptophan (5-HTP) 200 mg function test. Co-activation was investigated by administering metoclopramide 10 mg intravenously around the expected maximal effect of 5-HTP. The neuroendocrine effects were compared to those of metoclopramide alone, the 5-HTP test alone and matching placebo. Metoclopramide safely induced HPA-axis activation by itself, and potently synergized 5-HTP-induced corticotrophinergic activation of the HPA axis. These findings are indicative of vasopressinergic co-activation and suggest a role for metoclopramide as a practical function test for co-activation of the HPA axis. However, its application will be hampered pending clarification of the exact pharmacological mechanism by which metoclopramide induces co-activation of the HPA axis. (C) 2010 Elsevier B.V. and ECNP. All rights reserved. Show less
